BR112015012197A8 - usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos - Google Patents
usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmosInfo
- Publication number
- BR112015012197A8 BR112015012197A8 BR112015012197A BR112015012197A BR112015012197A8 BR 112015012197 A8 BR112015012197 A8 BR 112015012197A8 BR 112015012197 A BR112015012197 A BR 112015012197A BR 112015012197 A BR112015012197 A BR 112015012197A BR 112015012197 A8 BR112015012197 A8 BR 112015012197A8
- Authority
- BR
- Brazil
- Prior art keywords
- cdk
- pharmaceutical combination
- mtor inhibitor
- same
- inhibitor uses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
resumo patente de invenção: "terapia de combinação". a presente invenção refere-se a uma combinação farmacêutica que compreende (1) um primeiro agente que é um inibidor de cdk ou um seu sal farmaceuticamente aceitável e (2) um segundo agente que é um inibidor de mtor ou um seu sal farmaceuticamente aceitável.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261730661P | 2012-11-28 | 2012-11-28 | |
PCT/US2013/071659 WO2014085318A1 (en) | 2012-11-28 | 2013-11-25 | Combination therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015012197A2 BR112015012197A2 (pt) | 2017-07-11 |
BR112015012197A8 true BR112015012197A8 (pt) | 2019-10-01 |
Family
ID=49753505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015012197A BR112015012197A8 (pt) | 2012-11-28 | 2013-11-25 | usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos |
Country Status (12)
Country | Link |
---|---|
US (1) | US9408847B2 (pt) |
EP (1) | EP2925365A1 (pt) |
JP (2) | JP2016501221A (pt) |
KR (1) | KR20150089053A (pt) |
CN (1) | CN104812414A (pt) |
AU (4) | AU2013352406A1 (pt) |
BR (1) | BR112015012197A8 (pt) |
CA (1) | CA2891938A1 (pt) |
HK (1) | HK1211475A1 (pt) |
MX (1) | MX2015006809A (pt) |
RU (1) | RU2015125307A (pt) |
WO (1) | WO2014085318A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2676180T3 (es) * | 2011-07-01 | 2018-07-17 | Novartis Ag | Terapia de combinación que comprende un inhibidor de CDK4/6 y un inhibidor de PI3K para el uso en el tratamiento de cáncer |
CN105407889B (zh) | 2013-03-15 | 2018-06-01 | G1治疗公司 | 针对Rb阳性异常细胞增殖的HSPC节制性治疗 |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CN106103484B (zh) | 2014-03-14 | 2021-08-20 | 诺华股份有限公司 | 针对lag-3的抗体分子及其用途 |
SI3122426T1 (sl) | 2014-03-28 | 2023-04-28 | Duke University | Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CU20170052A7 (es) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
CN106336412A (zh) * | 2015-07-10 | 2017-01-18 | 南开大学 | 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物 |
SI3317301T1 (sl) | 2015-07-29 | 2021-10-29 | Novartis Ag | Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3 |
EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
EP3156406A1 (en) * | 2015-10-14 | 2017-04-19 | ratiopharm GmbH | Crystalline forms of ribociclib free base |
BR112018008904A2 (pt) | 2015-11-03 | 2018-11-27 | Janssen Biotech Inc | anticorpos que se ligam especificamente a tim-3 e seus usos |
CA3007671A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
WO2017223115A1 (en) * | 2016-06-22 | 2017-12-28 | Radius Health, Inc. | Ar+ breast cancer treatment methods |
EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
WO2018081211A1 (en) * | 2016-10-26 | 2018-05-03 | Li George Y | Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide |
US11083722B2 (en) | 2017-03-16 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
JP7433910B2 (ja) | 2017-06-22 | 2024-02-20 | ノバルティス アーゲー | Cd73に対する抗体分子及びその使用 |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
WO2020103922A1 (en) * | 2018-11-23 | 2020-05-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Novel pharmaceutical composition and use thereof |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5918214B2 (ja) | 2010-04-13 | 2016-05-18 | ノバルティス アーゲー | がんを治療するためのサイクリン依存性キナーゼ4またはサイクリン依存性キナーゼ(cdk4/6)阻害剤およびmtor阻害剤を含む組合せ |
-
2013
- 2013-11-25 CA CA2891938A patent/CA2891938A1/en not_active Abandoned
- 2013-11-25 EP EP13802807.1A patent/EP2925365A1/en not_active Withdrawn
- 2013-11-25 BR BR112015012197A patent/BR112015012197A8/pt not_active IP Right Cessation
- 2013-11-25 MX MX2015006809A patent/MX2015006809A/es unknown
- 2013-11-25 US US14/646,206 patent/US9408847B2/en not_active Expired - Fee Related
- 2013-11-25 AU AU2013352406A patent/AU2013352406A1/en not_active Abandoned
- 2013-11-25 KR KR1020157016810A patent/KR20150089053A/ko not_active Application Discontinuation
- 2013-11-25 CN CN201380061379.0A patent/CN104812414A/zh active Pending
- 2013-11-25 WO PCT/US2013/071659 patent/WO2014085318A1/en active Application Filing
- 2013-11-25 JP JP2015545145A patent/JP2016501221A/ja not_active Withdrawn
- 2013-11-25 RU RU2015125307A patent/RU2015125307A/ru not_active Application Discontinuation
-
2015
- 2015-12-14 HK HK15112282.5A patent/HK1211475A1/xx unknown
-
2016
- 2016-11-25 AU AU2016262781A patent/AU2016262781A1/en not_active Abandoned
-
2018
- 2018-01-15 AU AU2018200323A patent/AU2018200323A1/en not_active Abandoned
- 2018-09-20 JP JP2018176231A patent/JP2019031500A/ja not_active Withdrawn
-
2019
- 2019-02-08 AU AU2019200881A patent/AU2019200881A1/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
CA2891938A1 (en) | 2014-06-05 |
US9408847B2 (en) | 2016-08-09 |
AU2019200881A1 (en) | 2019-02-28 |
JP2016501221A (ja) | 2016-01-18 |
HK1211475A1 (en) | 2016-05-27 |
MX2015006809A (es) | 2015-08-06 |
EP2925365A1 (en) | 2015-10-07 |
RU2015125307A (ru) | 2017-01-10 |
AU2013352406A1 (en) | 2015-06-04 |
BR112015012197A2 (pt) | 2017-07-11 |
WO2014085318A1 (en) | 2014-06-05 |
CN104812414A (zh) | 2015-07-29 |
US20150306104A1 (en) | 2015-10-29 |
AU2016262781A1 (en) | 2016-12-15 |
AU2018200323A1 (en) | 2018-02-01 |
JP2019031500A (ja) | 2019-02-28 |
KR20150089053A (ko) | 2015-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015012197A8 (pt) | usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos | |
BR112016002465A2 (pt) | terapia da combinação para o tratamento de câncer | |
BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
BR112017006957A2 (pt) | formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína | |
BR112013027670A2 (pt) | "composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory" | |
BR112013022495A2 (pt) | formulação farmacêutica aquosa de tapentadol para administração oral | |
WO2015054619A8 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
BR112015007616A2 (pt) | inibidores de mek no tratamento de doenças por vírus | |
BR112015001419A2 (pt) | composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios | |
BR112014025711A8 (pt) | composto, medicamento, e, uso de um composto | |
BR112012021364A2 (pt) | "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas". | |
BR112016004358A8 (pt) | combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
BR112015017251A8 (pt) | composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas | |
BR112015030315A2 (pt) | derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo | |
BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. | |
BR112016006388A2 (pt) | inibidor seletivo da fosfatidilinositol 3-quinase gama | |
BR112015022092A2 (pt) | derivado de di-hidropiridazina-3,5-diona | |
BR112015026967A8 (pt) | fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica | |
BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
BR112015022982A2 (pt) | inibidores macrocíclicos de rip2 quinase | |
BR112015019919A2 (pt) | compostos bicíclicos | |
BR112015021265A2 (pt) | métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B06I | Technical and formal requirements: publication cancelled |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2605 DE 08-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |